Adriaan E Basson
Overview
Explore the profile of Adriaan E Basson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toti K, Pribut N, DErasmo M, Dasari M, Sharma S, Bartsch P, et al.
Front Pharmacol
. 2023 Jan;
13:1083284.
PMID: 36686712
Nucleoside- and nucleotide-based therapeutics are indispensable treatment options for patients suffering from malignant and viral diseases. These agents are most commonly administered to patients as prodrugs to maximize bioavailability and...
2.
Pribut N, DErasmo M, Dasari M, Giesler K, Iskandar S, Sharma S, et al.
J Med Chem
. 2021 Aug;
64(17):12917-12937.
PMID: 34459598
Tenofovir (TFV) is the cornerstone nucleotide reverse transcriptase inhibitor (NtRTI) in many combination antiretroviral therapies prescribed to patients living with HIV/AIDS. Due to poor cell permeability and oral bioavailability, TFV...
3.
Basson A, Charalambous S, Hoffmann C, Morris L
PLoS One
. 2020 Jun;
15(6):e0234937.
PMID: 32555643
We have previously reported on HIV-1 infected patients who fail anti-retroviral therapy but manage to re-suppress without a regimen change despite harbouring major drug resistance mutations. Here we explore phenotypic...
4.
Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant
Zondagh J, Basson A, Achilonu I, Morris L, Dirr H, Sayed Y
Antivir Ther
. 2019 Apr;
24(5):333-342.
PMID: 30958309
Background: Protease inhibitors form the main component of second-line antiretroviral treatment in South Africa. Despite their efficacy, mutations arising within the HIV-1 gag and protease coding regions contribute to the...
5.
Pribut N, Basson A, van Otterlo W, Liotta D, Pelly S
ACS Med Chem Lett
. 2019 Feb;
10(2):196-202.
PMID: 30783503
Since the discovery of HIV as the etiological agent of AIDS, the virus has infected millions of people each year. Fortunately, with the use of HAART, viremia can be suppressed...
6.
Pribut N, Veale C, Basson A, van Otterlo W, Pelly S
Bioorg Med Chem Lett
. 2016 Jun;
26(15):3700-4.
PMID: 27287366
The development of novel anti-HIV agents remains an important medicinal chemistry challenge given that no cure for the disease is imminent, and the continued use of current NNRTIs inevitably leads...
7.
Brigg S, Pribut N, Basson A, Avgenikos M, Venter R, Blackie M, et al.
Bioorg Med Chem Lett
. 2016 Feb;
26(6):1580-1584.
PMID: 26876929
In a previous communication we described a series of indole based NNRTIs which were potent inhibitors of HIV replication, both for the wild type and K103N strains of the virus....
8.
Giandhari J, Basson A, Sutherland K, Parry C, Cane P, Coovadia A, et al.
Antimicrob Agents Chemother
. 2016 Feb;
60(4):2248-56.
PMID: 26833162
Protease inhibitors (PIs) are used as a first-line regimen in HIV-1-infected children. Here we investigated the phenotypic consequences of amino acid changes in Gag and protease on lopinavir (LPV) and...
9.
Giandhari J, Basson A, Coovadia A, Kuhn L, Abrams E, Strehlau R, et al.
AIDS Res Hum Retroviruses
. 2015 Apr;
31(8):776-82.
PMID: 25919760
Studies have shown a low frequency of HIV-1 protease drug resistance mutations in patients failing protease inhibitor (PI)-based therapy. Recent studies have identified mutations in Gag as an alternate pathway...
10.
Basson A, Rhee S, Parry C, El-Khatib Z, Charalambous S, de Oliveira T, et al.
Antimicrob Agents Chemother
. 2014 Nov;
59(2):960-71.
PMID: 25421485
The objective of this study was to assess the phenotypic susceptibility of HIV-1 subtype C isolates, with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated amino acid changes, to newer NNRTIs. A...